Because MGMT promoter methylation and the resulting decrease in MGMT expression in brain tumors are associated with a better response to chemotherapy, greater overall survival, and longer time to disease progression [21,22], currently, molecular assays are routinely employed in glioma specimens for therapeutic design and prognostic measures [23,24]. The gene discussed is MGMT; the disease is brain neoplasm.